Petros Pharma receives Nasdaq delisting notice; trading to move to OTC Markets

Petros Pharmaceuticals, Inc.

Delisting due to failing minimum equity, bid price ($1.00), and public interest concerns from Feb 2025 offering.
Trading suspended on Nasdaq at open May 22, 2025; expected to trade on OTC Markets under PTPI.
Company has 15 days to appeal to Nasdaq Listing Council; appeal stays Form 25 but not suspension.
No assurance that Listing Council will grant continued listing on Nasdaq.

item 3.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.